GDF15 antibody (C-Term) (Biotin)
-
- Target See all GDF15 Antibodies
- GDF15 (Growth Differentiation Factor 15 (GDF15))
-
Binding Specificity
- C-Term
-
Reactivity
- Human, Mouse
-
Host
- Rabbit
-
Clonality
- Polyclonal
-
Conjugate
- This GDF15 antibody is conjugated to Biotin
-
Application
- Western Blotting (WB), ELISA, Immunohistochemistry (IHC)
- Purpose
- GDF15 Antibody Biotin Conjugated
- Cross-Reactivity (Details)
- This antibody reacts with the C-terminus of endogenous NAG-1 protein from human and mouse tissues.
- Characteristics
- Synonyms: rabbit anti-NAG1 antibody biotin conjugation, biotin conjugated rabbit anti-NAG1 antibody, NAG 1, NAG-1, GDF15, MIC1, MIC-1, GDF-15, PLAB, PTGFB, nonsteroidal anti-inflammatory drug-activated gene, NSAID-activated gene 1 protein, growth differentiation factor 15, macrophage inhibitory compound 1, Placental bone morphogenetic protein, Prostate differentiation factor
- Purification
- Nag-1 Antibody Biotin Conjugated antibody was affinity purified from monospecific antiserum by immunoaffinity chromatography.
- Immunogen
-
Immunogen: Nag-1 Antibody Biotin Conjugated antibody was prepared by repeated immunizations with a synthetic peptide corresponding to a region near the carboxy terminal end of human NAG-1 protein. A residue of cysteine was added to facilitate coupling to KLH.
Immunogen Type: Conjugated Peptide
- Isotype
- IgG
- Top Product
- Discover our top product GDF15 Primary Antibody
-
-
- Application Notes
-
Immunohistochemistry Dilution: 1:1,000-1:5,000
Application Note: NAG1/GDF15 Antibody Biotin Conjugated antibody has been tested by ELISA and western blotting of human and mouse NAG-1 protein. For detection of NAG-1 in human serum, a sandwich ELISA is suggested using this antibody in combination with anti-NAG-1/GDF15 (N-terminal), H variant or D variant specific antibodies. Specific conditions for reactivity should be optimized by the end user. Expect bands in Western blots of approximately 14 and 28 kDa in size corresponding to NAG-1 monomer and dimer, respectively, using the appropriate cell lysate or extract.
Western Blot Dilution: 1:2,000-1:10,000
ELISA Dilution: 1:20,000-1:100,000
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
-
Reconstitution Volume: 100 μL
Reconstitution Buffer: Restore with deionized water (or equivalent)
- Concentration
- 1.0 mg/mL
- Buffer
-
Buffer: 0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Stabilizer: 10 mg/mL Bovine Serum Albumin (BSA) - Immunoglobulin and Protease free
Preservative: 0.01 % (w/v) Sodium Azide - Preservative
- Sodium azide
- Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- 4 °C,-20 °C
- Storage Comment
- Store vial at 4° C prior to restoration. For extended storage aliquot contents and freeze at -20° C or below. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. This product is stable for several weeks at 4° C as an undiluted liquid. Dilute only prior to immediate use.
- Expiry Date
- 12 months
-
-
Changes in gene expression contribute to cancer prevention by COX inhibitors." in: Progress in lipid research, Vol. 45, Issue 1, pp. 1-16, (2006) (PubMed).
: "
-
Changes in gene expression contribute to cancer prevention by COX inhibitors." in: Progress in lipid research, Vol. 45, Issue 1, pp. 1-16, (2006) (PubMed).
-
- Target
- GDF15 (Growth Differentiation Factor 15 (GDF15))
- Alternative Name
- GDF15 (GDF15 Products)
- Background
- Background: Non-steroidal anti-inflammatory drug (NSAID) activated gene (NAG-1) is a member of the transforming growth factor-beta (TGF-beta) superfamily. NAG-1 is also known as Macrophage Inhibitory Cytokine-1 (MIC-1), Growth Differentiation Factor 15 (GDF15), Placental Bone Morphogenetic Protein (PLAB), or Prostate Derived Factor (PDF). NAG-1 is expressed in human placenta, prostate and colon. It possesses antitumorigenic and proapoptotic activities. NAG-1 expression is dramatically increased in inflammation, injury and malignancy. Increase of NAG-1 expression is a feature of many cancers including breast, colon, pancreas and prostate. In a number of studies, NAG-1 expression was increased by a number of NSAIDs. This increase in expression may correlate with the chemopreventive effect NSAIDs seem to have with certain cancers. NAG-1 expression is also induced by PPAR gamma ligands and by several dietary compounds such as conjugated linoleic acids (CLAs), naturally occurring fatty acids in ruminant food products, indoles, epicatechin gallate, and genistein. Induced expression of NAG-1 results in stimulation of apoptosis and inhibition of cell growth. Inhibition of NAG-1 induced expression by small interference RNA (siRNA) results in repression of induced apoptosis. NAG-1 expression is regulated by a numbers of transcription factors such as ERG-1 and Sp1. EGR-1 may be necessary for NSAID-induced NAG-1 expression. The study of expression of NAG-1 proteins, including variants, is important to define their potential role as serum biomarkers for cancer diagnosis, treatment monitoring, epidemiology study, and nutrition surveys.
- Gene ID
- 9518
- UniProt
- Q99988
- Pathways
- SARS-CoV-2 Protein Interactome
-